IDH1 and acute myeloid leukemia: IDH inhibitors (IDHi) selectively target mutant IDH enzymes, suppressing 2-HG production to restore metabolic homeostasis and normalize epigenetic patterns, thereby inducing AML cell differentiation while suppressing proliferation [116,117].